IL2 and metastatic melanoma: To date, IL-2 has been approved by the FDA as a treatment for advanced renal cell carcinoma and metastatic melanoma, and IFN-α has been approved as a treatment for hairy cell leukemia, follicular non-Hodgkin lymphoma, melanoma and AIDS-related Kaposi’s sarcoma19–21.